Cagri-semaglutide: what the research actually shows

What exactly is cagri-semaglutide, and how does the combination work?

Semaglutide you will probably recognise: it is the active ingredient in Wegovy and Ozempic, and it works by activating GLP-1 receptors that influence appetite, satiety and the rate at which the stomach empties. Cagrilintide is different. It mimics amylin, a hormone the pancreas releases alongside insulin at mealtimes, which signals fullness through a separate set of receptors in the brain. Pairing the two in one pen is an attempt to hit both pathways together rather than separately.

Novo Nordisk's reasoning is similar to why tirzepatide (which activates both GLP-1 and GIP receptors) outperformed semaglutide alone in the SURMOUNT-5 head-to-head trial. Adding a second hormonal signal appears to produce deeper appetite suppression than either agent can achieve alone. The cagrilintide component was first tested as a standalone injection before Novo Nordisk moved to the combination; the pairing is what defines cagri-semaglutide as its own investigational medicine. For a broader look at how semaglutide works on its own, our semaglutide overview covers the mechanism in plain terms.

Crucially, this is still an investigational product. Being in phase 3 trials means it has cleared early safety and dosing studies, but regulatory review by the MHRA and a NICE appraisal process would still need to follow before it could be prescribed in the UK. That process typically takes one to three years after a marketing authorisation application is submitted.

What did the REDEFINE trials actually find?

Novo Nordisk's REDEFINE 1 trial, which enrolled adults living with obesity who did not have type 2 diabetes, reported average weight reduction of roughly 22–23% from baseline over 68 weeks at the highest dose studied. A proportion of participants lost more than 25% of their body weight. Those are meaningful numbers: for context, the STEP 1 trial of semaglutide 2.4 mg, published in the New England Journal of Medicine, showed an average of around 15% weight loss over 68 weeks.

The results narrow the gap with tirzepatide significantly. They also raised immediate questions the research community is still working through: how durable is the loss after stopping treatment, what happens in people with type 2 diabetes, and how the side-effect profile compares at scale. Early data suggests the gastrointestinal side effects familiar from semaglutide alone (nausea, vomiting, constipation) remain present with the combination, though the relative rates across doses are still being characterised in ongoing arms of the programme.

What the trial data cannot yet tell us is how cagri-semaglutide performs across the more varied populations that a licensed medicine eventually reaches, or whether long-term cardiovascular and metabolic benefits match those already established for semaglutide on its own. Those questions will matter for any future NICE appraisal, which weighs cost-effectiveness against clinical benefit across the NHS population.

Can you get cagri-semaglutide in the UK today?

No. Until the MHRA grants a marketing authorisation, no UK pharmacy can legally dispense it. Any seller claiming to offer cagri-semaglutide in the UK right now is operating outside the law, and the product itself would not have gone through the manufacturing, quality and safety checks that authorised medicines require. The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss injections circulating online; you can report suspect sellers via the Yellow Card scheme.

If you are interested because of the semaglutide component, the good news is that you can access semaglutide legally now. Wegovy injection has been licensed in the UK for weight management since 2023, and the MHRA approved an oral semaglutide tablet for weight loss in June 2026. Our cagrilintide and semaglutide combination page goes further into how the two agents relate, including the dosing logic behind the combination. For people who want to understand where the dose research stands, the dosing chart for cagrilintide and semaglutide sets out the phase 3 schedule clearly.

Questions about whether treatment is right for you are ones a prescriber needs to answer based on your health history. Our clinical team reviews every consultation personally, and the FAQs page covers some of the most common questions people bring to us at that stage. If you are ready to explore what is currently licensed, a free consultation is the place to start.

Is there a cancer risk associated with semaglutide that applies here too?

The question comes up often, and it is a fair one to ask before committing to any semaglutide-containing medicine. Rodent studies found thyroid C-cell tumours at very high doses, which is why people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are excluded from treatment. Across the large human clinical trials conducted to date, including STEP 1 and the cardiovascular outcome trials, there has been no statistically significant increase in thyroid cancer in people. Our page on whether semaglutides cause cancer covers the evidence in detail, including what long-term registries are still watching for. The cost context for Wegovy is also worth reading if you are weighing up the private route alongside everything else.

The same contraindications relevant to semaglutide alone would logically apply to any semaglutide-containing combination. Until cagri-semaglutide has a licensed SmPC, the exact contraindication list for the combination cannot be definitive, which is another reason prescribing it in the UK is not currently possible. What a prescriber can do right now is assess whether the semaglutide that is licensed (Wegovy) is appropriate for you. That is a clinical conversation, and it starts with a consultation.